Vao Lili

Crinum asiaticum contains the alkaloid lycorine as its dominant bioactive compound, which inhibits nitric oxide production in macrophages and modulates COX-2 and TNF-α pathways to exert anti-inflammatory effects. In preclinical in vitro testing, a 95% ethanolic leaf extract achieved 98.26% inhibition of nitric oxide in LPS-stimulated RAW 264.7 macrophages at 100 µg/mL, with an IC50 of 16.66 ± 1.42 µg/mL.

Origin & History

Crinum asiaticum is a perennial bulbous herb native to tropical and subtropical Asia, including South and Southeast Asia, with naturalized populations across the Pacific Islands, including Samoa where it is known as Vao Lili. It thrives in coastal and lowland environments with moist, well-drained soils and is commonly found near shorelines, forest margins, and cultivated gardens throughout the Indo-Pacific region. The plant is cultivated in home gardens across Samoa, Indonesia, India, and Sri Lanka primarily for medicinal purposes, and grows readily in humid tropical climates with minimal agricultural input.

Historical & Cultural Context

Crinum asiaticum has a documented history of use in Ayurvedic medicine, where it is classified as tikta (bitter) and kashaya (astringent) in taste and used to pacify kapha and vata doshas, with applications directed toward inflammatory skin conditions, wounds, and joint disorders. In Samoa, the plant is known as Vao Lili and its bulb is applied traditionally for earache and wound treatment, reflecting the broader Pacific Islands tradition of using bulbous plants with strong antimicrobial properties for external injuries. In Indonesia, the plant is commonly called Ompu-ompu and figures in folk medicine traditions targeting bacterial infections, skin diseases, and as a general tonic, with preparations ranging from expressed juice to boiled decoctions applied topically or consumed in small quantities. The plant's distribution across Ayurvedic, Southeast Asian, and Pacific ethnobotanical traditions underscores its independent rediscovery as a medicinal resource across multiple indigenous knowledge systems, all converging on its bulb and leaf as the primary medicinal parts.

Health Benefits

- **Anti-inflammatory Activity**: Lycorine in leaf and bulb extracts suppresses nitric oxide production in activated macrophages and modulates pro-inflammatory cytokines including TNF-α and COX-2 enzymes, demonstrating potent in vitro anti-inflammatory effects.
- **Wound Healing Support**: The alkaloid crinamine promotes fibroblast proliferation and activity in rat models, accelerating tissue re-epithelialization and supporting the cellular repair process during wound healing.
- **Antioxidant Protection**: Phytochemical screening confirms the presence of flavonoids, phenols, and tannins in leaves and bulbs, which scavenge reactive oxygen species and contribute to measurable antioxidant capacity in extract assays.
- **Anticancer Potential**: Cycloneolitsol and hippeastrine isolated from methanolic leaf extracts exhibit mild cytotoxicity against HCT116 colorectal, Huh7 hepatocellular, and DU145 prostate cancer cell lines, with IC50 values ranging from 73.76 to 132.53 µM.
- **TRAIL-Sensitizing Activity**: Hippeastrine augments the apoptotic activity of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in AGS gastric cancer cells, yielding 34–36% greater cell death inhibition at concentrations of 20–30 µM compared to TRAIL alone.
- **Antibacterial Properties**: Alkaloid-rich ethanolic extracts of bulbs and leaves demonstrate antibacterial activity in vitro, attributed to lycorine and related Amaryllidaceae alkaloids that disrupt bacterial cell function, supporting traditional use for infected wounds.
- **Osteoclast Modulation**: In vivo evidence indicates lycorine decreases autophagy in osteoclasts, suggesting a potential role in modulating bone resorption processes, though this application remains exploratory and without clinical validation.

How It Works

Lycorine, the predominant Amaryllidaceae alkaloid in Crinum asiaticum, inhibits protein synthesis in inflammatory and tumor cells by blocking the elongation step of translation at the ribosomal level, thereby reducing the production of pro-inflammatory mediators including nitric oxide synthase (iNOS), TNF-α, and COX-2-derived prostaglandins in LPS-stimulated macrophages. Crinamine, another bulb-derived alkaloid, enhances fibroblast proliferation and migration by promoting growth factor signaling cascades involved in wound re-epithelialization, as demonstrated in rat excision wound models. Cycloneolitsol and hippeastrine exhibit cytotoxic and pro-apoptotic activity in cancer cell lines by mechanisms that include abrogation of TRAIL resistance, likely through modulation of anti-apoptotic Bcl-2 family proteins or activation of caspase cascades. Flavonoids and phenolic compounds in the leaf extracts contribute synergistic antioxidant effects by donating hydrogen atoms to neutralize reactive oxygen species and chelating transition metal ions that catalyze oxidative reactions.

Scientific Research

The current evidence base for Crinum asiaticum consists entirely of in vitro cell culture studies and animal models, with no published human clinical trials identified in the peer-reviewed literature. Key preclinical findings include NO inhibition assays in RAW 264.7 macrophages, cytotoxicity screening across HCT116, Huh7, DU145, and AGS cancer cell lines, and rat wound-healing models evaluating crinamine-containing preparations. Phytochemical profiling studies confirm the alkaloid content of leaves and bulbs through HPLC and spectroscopic methods, and the 95% ethanolic leaf extract has been identified as the most bioactive preparation for anti-inflammatory endpoints based on comparative solvent extraction studies. The absence of pharmacokinetic data, human bioavailability studies, dose-escalation trials, or randomized controlled trials means the existing evidence, while mechanistically plausible, cannot be extrapolated to clinical dosing or therapeutic recommendations.

Clinical Summary

No human clinical trials investigating Crinum asiaticum or its isolated constituents have been reported in available scientific literature, and the entire clinical evidence base is derived from in vitro and limited in vivo preclinical experiments. Preclinical outcomes demonstrate statistically significant NO inhibition (IC50 16.66 ± 1.42 µg/mL) and wound-healing acceleration in rat models, and cytotoxicity IC50 values in cancer cell lines range from 73.76 to 132.53 µM for isolated alkaloids cycloneolitsol and hippeastrine. These effect sizes are pharmacologically interesting but cannot be translated to human dosing without bridging pharmacokinetic, toxicological, and Phase I clinical data. Confidence in therapeutic recommendations for any indication is currently low, and Crinum asiaticum should be regarded as a candidate for further drug discovery research rather than an evidence-based clinical intervention.

Nutritional Profile

Crinum asiaticum bulbs and leaves are not consumed as a dietary food source and have not been analyzed for standard macronutrient or micronutrient content in nutritional databases. The primary phytochemical constituents of pharmacological relevance include Amaryllidaceae alkaloids—lycorine (most abundant, particularly in leaves and bulbs), crinamine, crinasiaticine, hippeastrine, and cycloneolitsol—alongside β-sitosterol, flavonoids, saponins, phenolic compounds, aldehydes, and terpenoids. Tannins are present in leaves but not bulbs based on phytoscreening data, and alkaloid content is rated strongly positive (++) in both plant parts. Exact quantitative concentrations of individual alkaloids across plant populations are not uniformly reported in the literature, and bioavailability of lycorine and related alkaloids in human subjects has not been characterized.

Preparation & Dosage

- **Bulb Decoction (Traditional)**: Fresh or dried bulb material boiled in water; no standardized dose established; used topically in Samoa for earache and wound application.
- **Ethanolic Leaf Extract (95%, Research Grade)**: Most active preparation identified in anti-inflammatory assays; used at 100 µg/mL in cell studies; no human dose established.
- **Methanolic Leaf Extract**: Used in laboratory isolation of cycloneolitsol, hippeastrine, and β-sitosterol; not a commercial supplemental form.
- **Bulb Powder**: Ground dried bulb used in Ayurvedic and Indonesian folk preparations; combined with carrier substances for topical application to wounds and inflamed skin.
- **Tincture**: Alcohol-based extraction of bulb or leaf material used in traditional folk medicine systems; no standardized alkaloid concentration or dose range defined.
- **Note**: No standardized commercial supplement forms, validated dose ranges, or bioavailability data exist; purification of lycorine-containing extracts is recommended in research contexts to manage cytotoxicity at high concentrations.

Synergy & Pairings

In Ayurvedic practice, Crinum asiaticum is traditionally combined with ashwagandha (Withania somnifera) for synergistic anti-inflammatory and adaptogenic effects, with withanolides from ashwagandha complementing lycorine's COX-2 and TNF-α modulation through independent NF-κB inhibitory pathways. Hippeastrine's ability to sensitize cancer cells to TRAIL-mediated apoptosis suggests potential synergy with other pro-apoptotic agents that activate death receptor pathways, representing a mechanistically rational combination in oncology research contexts. The flavonoid and phenolic content of Crinum asiaticum extracts may synergize with exogenous antioxidants such as vitamin C or green tea catechins to enhance reactive oxygen species scavenging beyond what either component achieves alone.

Safety & Interactions

Crude high-dose extracts of Crinum asiaticum demonstrate cytotoxicity in cell-based assays, attributed primarily to lycorine, which inhibits protein synthesis non-selectively at elevated concentrations, raising concern for systemic toxicity if ingested in unrefined forms. No formal clinical toxicology studies, LD50 values in human-relevant models, or established maximum safe doses have been published, and the plant should be treated with caution given the known toxicity of Amaryllidaceae alkaloids as a class, which includes emetic and neurotoxic effects in animals. No specific drug-drug interaction data exists, but lycorine's inhibition of protein synthesis and potential modulation of cytokine pathways theoretically warrants caution when combined with immunosuppressants, chemotherapeutic agents, or anti-inflammatory drugs. The plant is contraindicated for internal use during pregnancy and lactation based on general alkaloid toxicity principles and the absence of safety data in these populations; topical use should also avoid mucous membranes and broken skin without clinical oversight.